Through detailed computer-based analyses of publicly available genetic data sets, a team of scientists in China has identified three genes that are overactive in people with Sjögren’s disease, according to a study. The scientists are hopeful that, with further validation, these genes may be used as markers to aid…
A global clinical trial testing Immunovant’s injection therapy IMVT-1402 against a placebo in adults with Sjögren’s disease is still recruiting participants, and remains on track to provide initial data in 2028. That’s according to a press release from the company, a Roivant subsidiary, announcing Immunovant’s latest…
Dianthus Therapeutics has selected Sjögren’s disease as one of the first three priority indications for the clinical development of DNTH212, its experimental therapy for autoimmune conditions. The treatment is currently being tested in healthy adult volunteers in a China-based Phase 1 clinical trial (NCT07323173), with top-line data…
Efgartigimod, a therapy approved for certain autoimmune diseases, led to higher response rates and greater reductions in certain immune markers than a placebo in adults with Sjögren’s disease, according to final data from a small proof-of-concept clinical trial. Because the Phase 2 study, called RHO (NCT05817669), was not…
Get regular updates to your inbox.
